Dr Dan Littman joins Pfizer’s Board of Directors & Corporate Governance and Science and Technology Committees

Amy Schofield 06 March 2018

Pfizer has announced the election of Dr Dan R. Littman to its Board of Directors. Dr Littman, age 65, was also appointed to the Corporate Governance and Science and Technology Committees of Pfizer’s Board.

Dr Littman is the Helen L. and Martin S. Kimmel Professor of Molecular Immunology at the Skirball Institute of Biomolecular Medicine of NYU Langone Medical Center and an Investigator of the Howard Hughes Medical Institute. Prior to joining NYU in 1995, he was a Professor of Microbiology and Immunology at the University of California, San Francisco.

He is also a member of the National Academy of the Sciences and the Institute of Medicine, and is a Fellow of the American Academy of Arts and Sciences and the American Academy of Microbiology.

Dr Littman received an A.B. in Biochemical Sciences from Princeton University and an M.D. and Ph.D. from Washington University School of Medicine.

Ian Read, Chairman and Chief Executive Officer, Pfizer, said: “We are pleased to welcome a renowned immunologist to Pfizer’s Board of Directors. Dr. Littman has made extraordinary scientific contributions throughout his career and will be a tremendous asset to the company. The addition of Dan to the board helps to ensure that Pfizer will continue to benefit from a breadth and diversity of experience.”

Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.